Sinohealth Technology Holdings Limited
2361.HK
Hong Kong Stock Exchange4.99
HKD
+0.24
- -
ISIN
KYG8192Q1064
Return %
Stock
S&P500
1Y
57.41
23.08
3Y
14.71
67.59
5Y
-6.90
74.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yushu Wu
- Full Time Employees
- 785
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- No.5 Wangjiang Second Street Guangzhou GD People's Republic of China
- IPO Date
- Jul 12, 2022
- Website
- ir.sinohealth.cn
- Similar Companies
- Business
- Sinohealth Technology Holdings Limited (HKEx: 2361.HK) engages in data-driven health industry solutions and SaaS platforms for medical product manufacturers, retailers, healthcare institutions, and related participants, with a strategic emphasis on AI-enabled analytics and in-hospital decision-support capabilities. Main Products and Services - Data Insight Solutions: growth and investment decision platforms; data-driven marketing and market intelligence tools; customer and partner analytics designed for medical device and pharmaceutical stakeholders; data aggregation, cleansing, and visualization services. - AI-Driven SaaS Platforms: Smart Decision Cloud and related data-as-a-service offerings enabling decision support for clinical and commercial workflows; AI-based health management modules including patient follow-up, chronic disease management, and private-domain member management; integration with hospital information systems and medical device supply networks. - Data-Driven Publications and Events: industry publications, targeted research reports, and events designed to connect manufacturers, distributors, and healthcare providers with actionable market insights. - Standard SaaS Applications: sector-specific software for medical product manufacturers, retail pharmacies, physical examination centers, and medical services providers; workflow automation, patient engagement modules, inventory and procurement support, and performance analytics. - In-hospital Solutions: innovative models for hospital-based services, including AI-enabled MDT (multi-disciplinary team) collaboration platforms, in-hospital patient management systems, and clinical decision support tools that streamline drug management, follow-ups, and care coordination. Latest Major Company Changes - AI Enablement and Proceeds Utilization: reallocates remaining IPO proceeds toward accelerated AI development, AI research and database enhancements, and strategic acquisitions to strengthen the AI services ecosystem, with full deployment targeted by late 2028 and a dedicated pool for strategic investments. - AI Strategy Expansion and Partnerships: pursues rapid scale-up of AI-driven in-hospital services, including maturation of AI-based patient management and clinical decision platforms, coupled with ongoing collaboration with healthcare providers and pharmaceutical partners to broaden adoption (context from regulatory and market disclosures in 2025–2026 filings). - Corporate Reorganization and Technology Upgrade: transition from traditional SaaS operations to upgraded platform architectures and commercialized AI-enabled solutions in 2025, positioning the company for greater data-driven health services reach. - Capital and Financing Movements: updates to capital deployment and strategic investment plans reflect a refined AI-centered growth trajectory, including consideration of acquisitions to bolster AI capabilities and healthcare ecosystem integration (as indicated in 2025–2026 market communications). Additional Context - Industry and Segments: health data analytics and AI-enabled health technology; data insight solutions, data-driven publications/events, and SaaS health platforms; supports medical product manufacturers, healthcare providers, and retail/pharmacy networks. - Target Markets: medical product manufacturers, pharmaceutical retailers, healthcare institutions, physical examination centers, and patients benefiting from digital health management solutions. - Geographic Operations: primary focus on China with global data and AI infrastructure considerations; involvement in in-hospital and healthcare ecosystem initiatives that align with regional market expansion and cross-border data collaboration. - Founding Year and Headquarters: established in the early 2010s with headquarters in China; listed on the Hong Kong Stock Exchange, indicating a formal corporate structure and international investor access. - Subsidiaries/Parent Relationships: operates as a holding company with specialized platforms and product lines under Sinohealth branding; maintains relationships with hospital networks, pharmaceutical suppliers, and medical service entities through its data and SaaS offerings. Notes on sources and disclosures - The company has publicly disclosed shifts toward AI-centric product development and strategic use of IPO proceeds to fund AI upgrades and acquisitions, reflecting a broader industry push toward data-enabled health solutions. - Regulatory filings and market disclosures indicate ongoing evolution of in-hospital and data-driven solutions, including the maturation of AI-based business models and expansion of service offerings to a broader healthcare ecosystem. - External coverage notes a strategic reallocation of IPO proceeds to accelerate AI initiatives and strategic investments, with deployment targeted by 2028, reinforcing the company’s emphasis on AI-powered health services. Note: This description synthesizes publicly available information as of 2025–2026 to provide a current, concise overview suitable for financial databases and investment research.